High-Dose Vitamin C IV Therapy During Cancer Care: What Patients and Caregivers Should Know

Why IV vitamin C is different from taking vitamin C by mouth

Vitamin C is an essential nutrient involved in normal immune function, antioxidant activity, collagen formation, and tissue repair.

Your body tightly controls how much vitamin C it absorbs from food or oral supplements. As oral doses increase, the percentage absorbed falls, and much of the excess is eliminated through the urine.

IV administration bypasses that digestive limitation. This allows vitamin C concentrations in the blood to rise far higher than they can through oral supplementation. That pharmacologic difference is the reason researchers study intravenous vitamin C separately from vitamin C tablets or food.

It is important to understand what that difference does—and does not—tell us.

It tells us that oral and intravenous vitamin C are not interchangeable in research. It does not prove that achieving a higher blood concentration will improve a particular person’s cancer outcome.

Why researchers are studying HDVC in cancer care

At ordinary concentrations, vitamin C acts primarily as an antioxidant. At the much higher concentrations produced through IV administration, it can behave differently in laboratory settings.

Researchers have studied whether pharmacologic concentrations of vitamin C can create oxidative stress that affects some cancer cells, whether it can be safely combined with specific cancer treatments, and whether it may influence treatment tolerance or quality of life.

Laboratory findings are useful because they help researchers decide what deserves human testing. But cancer cells in a dish, animal studies, and early-phase human trials are not the same as proving that a treatment helps patients live longer or improves their disease.

That distinction matters because HDVC research has produced a mixture of promising and negative results.

What the clinical research has found so far

A promising pancreatic cancer study

A randomized phase II study published in 2024 evaluated 34 treated patients with metastatic pancreatic cancer. Participants received standard gemcitabine and nab-paclitaxel chemotherapy either with or without 75 grams of pharmacologic IV vitamin C three times per week.

In that study, the group receiving IV vitamin C had a median overall survival of 16 months compared with 8.3 months in the standard-treatment group. Median progression-free survival was also longer, and the researchers did not observe an increase in the frequency or severity of adverse events.

Those results are encouraging. They are also the findings of one relatively small phase II trial involving one cancer type and one chemotherapy combination. Larger studies are needed before the results can be treated as broadly applicable or practice-changing.

A negative prostate cancer study

A different randomized, double-blind phase II study published in 2024 evaluated IV vitamin C combined with docetaxel in 47 men with metastatic castration-resistant prostate cancer.

That study did not find a significant improvement in PSA response, progression-free survival, quality of life, treatment toxicity, or other measured clinical outcomes. The trial was stopped after an interim analysis indicated that it was unlikely to meet its primary goals.

The researchers concluded that their findings did not support routine use of HDVC for that patient population outside clinical trials.

Earlier studies and quality-of-life questions

Smaller trials and observational studies have reported possible improvements in quality of life or reductions in some treatment-related symptoms. Early studies have also examined whether IV vitamin C can be combined safely with particular chemotherapy regimens.

These studies help establish feasibility and identify questions worth pursuing. Many were small, uncontrolled, or not designed to determine whether HDVC improves survival. The National Cancer Institute describes the overall human evidence as mixed and notes important limitations in the available trial designs.

What “promising research” actually means

It is understandable to see a favorable study and feel hopeful. Hope and scientific caution are not opposites.

A phase I trial generally focuses on safety, dosing, and tolerability. A phase II trial looks for a meaningful signal that may justify a larger study. A phase III trial typically compares an intervention with standard care in a larger population and is designed to provide much stronger evidence about whether it should become part of routine treatment.

HDVC has produced enough scientific interest to justify continued study. It has not produced consistent enough evidence across cancer types and treatment combinations to be considered a proven cancer therapy.

One positive trial does not establish that HDVC works for every cancer. One negative trial does not establish that no patient or cancer type could benefit. Together, the studies show why treatment-specific research and larger randomized trials matter.

Is HDVC best understood as cancer treatment or supportive care?

At purelyIV, HDVC is offered only as adjunctive wellness support. It is not presented as a treatment for cancer.

“Adjunctive” means something considered alongside established medical care—not instead of it.

A person may ask about HDVC because they are interested in antioxidant support, immune wellness, recovery, or emerging oncology research. The appropriate question is not simply, “Does vitamin C help cancer?”

A more useful discussion includes:

• What type and stage of cancer is involved?
• What treatment is the oncology team providing?
• What goal does the patient have in considering HDVC?
• Is there research involving that cancer and treatment combination?
• Are there safety or interaction concerns?
• How would the patient and clinicians decide whether continuing makes sense?

The oncology team should remain primary in any decision involving cancer treatment, treatment timing, medication interactions, or changes in symptoms.

Vitamin C, collagen, and wound healing

Vitamin C is required for collagen production. Collagen is a major structural component of skin and connective tissue and plays an important role in normal wound healing.

This established biological role is one reason people ask whether vitamin C could support healing after surgery, tissue injury, or other physical stress.

That biological connection should not be stretched into a promise that HDVC will make a surgical wound, chronic wound, radiation-related injury, or other wound heal faster.

Research specific to high-dose IV vitamin C as an outpatient wound-healing treatment remains limited. Any wound that is painful, worsening, infected, opening, draining, or slow to heal needs appropriate medical or wound-care evaluation. HDVC should not replace treatment of the wound or its underlying cause.

Why G6PD screening is required

G6PD stands for glucose-6-phosphate dehydrogenase. It is an enzyme that helps protect red blood cells from oxidative damage.

A person with G6PD deficiency may be at risk of hemolysis—rapid breakdown of red blood cells—when exposed to high doses of vitamin C. That is why a current G6PD result is required before purelyIV approves HDVC treatment.

G6PD testing is not a formality. It is a meaningful safety screen.

The clinical review should also consider kidney disease, a history of kidney stones, iron-overload conditions such as hemochromatosis, medications, current symptoms, and other factors that could affect treatment fit. High-dose IV vitamin C may also interfere with certain point-of-care glucose measurements, which is another reason the complete health history and current care plan matter.

Have questions before you decide?

You do not need to know which dose to request before contacting purelyIV. Our team can explain the G6PD requirement, available dose options, clinical-review process, and what information we need from you and your care team.

NP oversight RN-delivered care At-home care G6PD review required

Call About HDVC View HDVC Dose Options

Questions to discuss with your oncology team

Bringing a focused set of questions to your oncologist can lead to a more useful conversation than asking only whether vitamin C is “good” or “bad.”

Consider asking:

• Are there reasons HDVC would be inappropriate with my diagnosis or treatment plan?
• Is there any known concern with the specific chemotherapy, immunotherapy, targeted therapy, or radiation treatment I am receiving?
• Does the timing of an infusion matter in relation to my cancer treatments?
• Are there laboratory results or kidney concerns that should be reviewed first?
• Is there research involving HDVC and my particular cancer type?
• What goal would be reasonable—supportive wellness, treatment tolerance, quality of life, or something else?
• Are there symptoms that should be evaluated by the oncology team rather than managed through supportive care?
• How should all members of my care team communicate about the treatments and supplements I am receiving?

A clinician who offers HDVC should be comfortable with your oncology team remaining involved. You should not be pressured to hide supportive treatments from your oncologist or to choose them instead of established care.

Questions to ask an HDVC provider

The provider administering the infusion also has responsibilities.

Useful questions include:

• Who reviews my health history and approves treatment?
• Is a current G6PD result required?
• What other laboratory information may be needed?
• Which doses are available, and how is the dose selected?
• How long will the visit take?
• Who administers and monitors the infusion?
• What symptoms or changes should be reported before the visit?
• What would cause the provider to postpone or decline treatment?
• How will the provider coordinate with my existing care plan?
• What claims does the provider make about expected results?

Be cautious when a provider guarantees a cancer response, promises that HDVC will make chemotherapy work, describes it as a cure, or minimizes the role of your oncology team.

What the purelyIV HDVC process looks like

purelyIV offers 25g, 50g, 75g, and 100g HDVC options. The process begins with a conversation and clinical review rather than automatic treatment confirmation.

A recent G6PD result is required. You may provide acceptable recent results or purchase the required lab directly through purelyIV. A nurse practitioner then reviews your intake, medications, health history, goals, and laboratory information before treatment is approved.

When clinically appropriate, a registered nurse brings the infusion to your home, office, or hotel and monitors the visit. Most appointments take approximately 60 to 90 minutes, depending on the dose, setup, and infusion tolerance.

purelyIV’s clinical protocols are led by Erin Boumansour, MSN, ACNP-BC. Her background includes oncology, critical care, palliative care, hospice, emergency medicine, and prior nurse practitioner experience at Memorial Sloan Kettering Cancer Center. That experience helps shape a thoughtful approach while keeping each client’s oncology team and established treatment plan primary.

Frequently asked questions

Is high-dose IV vitamin C an FDA-approved cancer treatment?

No. The FDA has not approved high-dose IV vitamin C as a cancer treatment. It continues to be studied alone and in combination with certain conventional cancer treatments.

Can HDVC be used during chemotherapy?

HDVC has been studied with some chemotherapy regimens, but the findings cannot be generalized to every medication, cancer type, or patient. Your oncology team should review the specific treatment combination and timing before you proceed.

Is an IV infusion equivalent to taking a large oral vitamin C dose?

No. Oral absorption is limited, while IV administration can produce much higher blood concentrations. That pharmacologic difference is why oral and IV vitamin C must be evaluated separately.

Why do I need a G6PD test?

G6PD deficiency can make high-dose vitamin C dangerous because of the risk of hemolysis. A current result allows the reviewing clinician to screen for that risk before treatment.

Can HDVC improve wound healing?

Vitamin C is necessary for collagen production and normal wound healing. That does not establish that high-dose IV vitamin C will accelerate healing of a particular wound. Evidence specific to HDVC for wound healing remains limited, and medical wound care should remain primary.

The bottom line

HDVC research deserves neither exaggerated promises nor automatic dismissal.

Some studies have reported encouraging findings. Others have found no clinical benefit. The evidence is still evolving, appears to vary by cancer type and treatment combination, and is not strong enough to make HDVC a substitute for established oncology care.

For a patient or caregiver, the safest and most useful next step is a coordinated conversation: understand the goal, involve the oncology team, complete appropriate screening, and choose a provider who is honest about both the research and its limitations.

Start with a conversation, not a commitment

If you are exploring high-dose vitamin C during cancer care or survivorship, purelyIV can help you understand the dose options, G6PD testing, and clinical-review process before you decide whether to request treatment.

NP oversight RN-delivered care At-home care G6PD review required

Call About HDVC Text About HDVC